Treatment of Hyperprolactinemia in Symptomatic Prolactin-Secreting Pituitary Microadenoma or Macroadenoma

Clinical Scenario

This protocol applies to patients with hyperprolactinemia caused by a symptomatic prolactin-secreting pituitary microadenoma or macroadenoma. Both lowering prolactin and reducing pituitary tumor size are core therapeutic objectives.

Treatment Approach

The recommended first-line strategy centres on a targeted class of medical therapy with established efficacy for both hormonal control and tumor reduction in this setting. A specific preferred agent within this class is indicated — the full regimen, agent selection rationale, and dosing algorithm are detailed in the structured protocol.

Treatment Goals

Normalization of serum prolactin levels and significant reduction in pituitary tumor size. Normoprolactinemia is commonly achieved within 6 months of initiating treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2010-1692

We recommend dopamine agonist therapy to lower prolactin levels, decrease tumor size, and restore gonadal function for patients harboring symptomatic prolactin-secreting microadenomas or macroadenomas.

In a prospective study of 26 treatment-naive patients with macroprolactinomas, normoprolactinemia was achieved within 6 months in 81% of patients receiving 0.25–2 mg cabergoline weekly, and 92% exhibited significant tumor shrinkage.

View source ↗